Susquehanna Fundamental Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$258K	Buy	+16,683	New	+$260K	0.01%	810

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Susquehanna Fundamental Investments's CPRX Position: Q2 2024 in Review

Susquehanna Fundamental Investments opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2024: 16,683 shares worth $258K. The stake represents 0.01% of the portfolio and ranks #810 among its holdings.

271 funds tracked by Wall St. Rank hold CPRX as of Q2 2024.

Susquehanna Fundamental Investments held 16,683 shares of Catalyst Pharmaceutical worth $258K as of Q2 2024.
Catalyst Pharmaceutical was a new Susquehanna Fundamental Investments position in Q2 2024.
Catalyst Pharmaceutical made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2024, its #810 holding.
271 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.